Denka Company Limited Overview
Denka is a 111-year-old, mid-cap Japanese specialty and commodity chemical maker. It is moving from carbide-derived commodity chemistry toward high-value inorganic and organic materials for AI semiconductors and power infrastructure, plus a healthcare franchise in vaccines and diagnostics. Its competitive core is powder and particle engineering:
-
spherical fused silica and spherical alumina fillers for advanced semiconductor packaging;
-
acetylene black for high-voltage cables and energy storage;
-
ALSINK and silicon-nitride heat-dissipation materials for power modules;
-
the newly commercialised SNECTON low-dielectric resin for AI server substrates.
These growth franchises are tied to legacy businesses that are cyclical or structurally challenged: chloroprene rubber, styrenics and special cement additives. Those legacy businesses drove a 2023–2025 earnings collapse, including a ¥12.3bn net loss in FY3/25 caused by the US DPE chloroprene plant. Under CEO Ikuo Ishida, the "Mission 2030 Phase 2" plan (FY3/27–FY3/29) aims to:
-
rebuild earning power to record operating income;
-
reach ROE of at least 8%;
-
exit DPE;
-
prepare a spin-off of the styrene business by April 2027.
Company's own description
The FY3/26 Annual Securities Report says the group's main business is manufacturing and selling products in four reportable segments, plus related services (plant engineering and trading in "Others"):
-
Electronics & Innovative Products (E&I)
-
Life Innovation (LI)
-
Elastomers & Infrastructure Solutions (E&IS)
-
Polymer Solutions (PS)
The company's stated corporate Purpose under Mission 2030 is to "Make the world a better place as specialists in chemistry" (Mission 2030 Phase 2 notice, 27 Feb 2026).
Independent characterisation
Denka is a vertically integrated, manufacturing-led materials company. Its revenue is almost entirely product sales; there are no meaningful subscription or licensing revenues. Its origins in hydro-powered calcium carbide production at the Omi Plant (Itoigawa, Niigata) explain its unusual combination of businesses:
-
the acetylene chain: carbide → acetylene → acetylene black and chloroprene;
-
inorganic high-temperature processing: fused silica, alumina, nitrides;
-
a separate petrochemical chain based on naphtha-derived styrene at the Chiba Plant;
-
a biologics and diagnostics business inherited from Denka Seiken, absorbed in April 2020.
Revenue model mix (analyst estimate from segment structure):
-
More than 98% product sales, about 2% engineering services (in "Others"). The company does not disclose this mix.
-
In Life Innovation, influenza vaccines are sold mainly under Japanese public-health procurement channels. Diagnostic kits are sold through distributors to clinics and hospitals.
-
In E&I, products are qualified by customers ("spec-in"), so revenue is sticky once a material is designed into a substrate or package.
-
In PS and E&IS, prices are commodity-linked. Many contracts include raw-material pass-through formulae, which create inventory-valuation timing effects (Q1 FY3/27 inventory gain of +¥6.0bn).
Value-chain position:
Mid-stream supplier of engineered materials: Fillers go to epoxy-molding-compound makers and copper-clad-laminate (CCL) makers. Acetylene black goes to cable compound and battery makers. Ceramic substrates go to power-module makers.
Upstream monomer and polymer producer: Styrene monomer, ABS/AS/SBC/MS resins, and chloroprene rubber.
Downstream branded healthcare products: Vaccines, rapid-antigen test kits, in-vitro diagnostic (IVD) reagents.
Customer types and end-markets (FY3/26 E&I application mix per company):
-
AI-related semiconductors and power infrastructure (high-voltage cables, energy storage systems, DC transmission) together make up a rising share of E&I sales. The company chart shows AI-related applications at about 21–24% and power infrastructure at about 11–15% of segment sales.
-
Other end-markets: general-purpose semiconductors and electronic components; xEV and automotive; electric railways.
-
Healthcare: clinics and hospitals (rapid tests), national influenza-vaccine programmes, laboratories (IVD and Kainos reagents).
-
Construction and infrastructure: special cement additives; corrugated pipes for agricultural and civil-engineering use.
-
Automotive and industrial rubber: chloroprene for belts, hoses, adhesives, wetsuits and medical gloves.
-
Consumer and industrial plastics: PC monitors (MS-resin light-guide plates), appliances, general merchandise, food packaging sheets and containers.
-
Wig and hairpiece fibre: Toyokalon, mainly for African markets.
-
No single customer exceeds 10% of net sales (FY3/26 Tanshin).
Strategy
Mission 2030 — evolution
The original plan (announced November 2022, covering FY3/24–FY3/31):
-
framed strategy around three themes: Business Value Creation, Human Resources Value Creation and Management Value Creation;
-
targeted FY2030 operating income of ¥100bn and ROE of 15%;
-
included an environmental investment budget of ¥85bn over 8 years.
Phase 1 (FY3/24–FY3/26) badly missed its trajectory. Management named the reasons: a slump in electronic-material demand, weak US chloroprene performance, slower-than-expected payback on EV-related investments, and higher fixed costs.
Mission 2030 Phase 2 (FY3/27–FY3/29), announced 27 February 2026
| Phase 2 targets (JPY Bn) | FY3/26A | FY3/27 plan | FY3/27 guidance | FY3/28 plan | FY3/29 plan |
|---|---|---|---|---|---|
| Operating income | 26.2 | 35.0 | 30.0 | 40.0 | 45.0 |
| Net income | 15.7 | 18.0 | 16.0 | 22.0 | 26.0 |
| ROE (%) | 5.2 | — | 5.1 | — | 8.0 |
The presentation is titled "Rebuilding Earning Power: The Start of a New Growth Phase." It sets three key measures:
-
Strengthen growth businesses in ICT & Energy and Healthcare.
-
Turn Sustainable Living into cash cows by keeping only competitively sustainable businesses.
-
Resolve DPE early and minimise the financial burden. A closure plan is targeted early in Phase 2.
Supporting elements:
-
Business units are reclassified as growth drivers, stable earners or cash cows.
-
Investment is tightly selected to restore the balance sheet.
-
At least ten new business initiatives are to be seeded for the post-2030 period.
-
Non-financial targets cover emissions, safety and more women in management.
Notes on the targets:
Source: Mission 2030 Phase 2 notice and presentation (27 Feb 2026); FY3/26 Results Presentation.
ROE target: at least 8% in any year of Phase 2, by FY3/29 at the latest.
Implied record: the FY3/29 target of ¥45bn would be a record, above FY3/22's ¥40.1bn.
Shareholder returns: a cumulative 50% total return ratio over the eight-year plan, with DPS maintained or increased.
Strategic initiatives register (last 24 months)
| Date | Initiative | Type | Detail and targets |
|---|---|---|---|
| Sep 2024 → Mar 2026 | Ofuna Plant suspension and land sale | Footprint rationalisation | Land of 46,912 m² sold (Mar 2025 agreement); ¥8.2bn gain in FY3/26 |
| Feb 2025 → May 2026 | SNECTON launch and dedicated plant | New-product platform | AI/5G low-Df resin; plant done May 2026; full-swing AI sales from 2H FY3/27 |
| Apr 2025 | D-NODE™ styrene chemical-recycling brand | Circularity | Closed-loop styrene materials |
| Apr 2025 | Revised policy on low-carbon acetylene (methane-to-acetylene) development | Decarbonisation technology | Change in development approach (details in release) |
| May 2025 | ALSINK capacity reinforcement | Capacity | Power-module demand |
| May 2025 | Gosen diagnostic-reagent building | Capacity | Antigen kits |
| May 2025 | DPE production suspension | Restructuring | +¥8.8bn OI (FY3/26) and +¥15.0bn (FY3/27 vs FY3/25) planned |
| FY3/25 onward | Best Practices Project (cost) | Cost programme | P&L-factored savings: ¥0.9bn (FY3/25), ¥3.7bn (FY3/26), ¥6.8bn target (FY3/27). Total impact incl. avoided costs: ¥1.3bn, ¥5.5bn, ¥10.0bn. |
| Sep 2025 | Imerys alliance in special cement additives | Partnership | Calcium-aluminate technology; low-carbon products for Europe |
| Oct 2025 | CVC investment in a South Korean startup (thermal-conductive filler) | Venture investment | Heat-dissipation fillers |
| Feb 2026 | Kainos Laboratories tender offer | M&A | IVD reagents; co-funded with Development Bank of Japan |
| Feb 2026 | Styrene business spin-off review | Portfolio | Target April 2027 |
| Mar 2026 | Toyo Styrene stake raised to 65% | Consolidation | Prerequisite for the styrene restructuring |
| Jul 2026 | Flosonics Medical investment | Digital health CVC | Wearable ultrasound |
| Jul 2026 | DENKA ER exit | Portfolio pruning | Production ends Aug 2028 |
| Aug 2026 | Accelerated rollout of chemically recycled styrenics | Circularity | Mass-balance environmental value |
| Ongoing | Thailand acetylene black plant (SCGC JV) | Capacity | Power-cable and ESS demand |
Sustainability commitments
-
Carbon neutrality (Scope 1+2) by FY2050.
-
60% reduction versus FY2013 by FY2030.
-
150 MW maximum renewable output (KPI).
-
Zero final waste disposal.
-
Chemical-recycling consortium; "CUCO" carbon-negative concrete.
Products & Services
Pricing is generally not publicly disclosed; it is negotiated B2B, and NHI/public tender applies for vaccines. Launch years are given where disclosed.
Electronics & Innovative Products
| Product line | Description and key capabilities | Target customer | Launch / status | Flagship notes |
|---|---|---|---|---|
| SNECTON® (soft-type) | Low-dielectric organic insulating resin; per Denka, the only material combining very low dissipation factor (Df) with good processability. Used as the resin component of rigid CCLs. | CCL makers for AI server motherboards and IC substrates | Launched Feb 2025; dedicated plant completed May 2026; samples shipped Aug 2026 | Progressing toward de-facto standard in the M9-equivalent grade; M10-grade evaluations favourable; AI-related sales to ramp fully from 2H FY3/27 |
| SNECTON (hard-type) | Harder grade for different laminate architectures | CCL makers | Under development; final-stage capacity-expansion review | Being repositioned toward higher value-added uses after user feedback (Aug 2026) |
| Low-dielectric organic filler (new) | Spherical, PFAS-free filler with PTFE-like low Dk (2.3) and Df (0.0006); lower CTE and specific gravity than PTFE fillers | FCCL (fluorinated hybrid polyimide) and rigid-CCL makers | Introduced Aug 2026 (development) | Pairs with inorganic fillers in an "organic/inorganic" materials strategy |
| Spherical fused silica (incl. low-Df grade) | High-purity spherical SiO₂ fillers. Low-Df grade has Df ≤0.0010; Dk 3.8; CTE 0.5 ppm/°C. | Resin-substrate and CCL makers; semiconductor epoxy molding compounds; optical-ferrule makers | Fused silica since 1971; low-Df grade in volume growth | Strong AI demand; optical-ferrule demand surged in FY3/26 |
| Spherical alumina | Thermally conductive spherical Al₂O₃ fillers across particle sizes; fine powders made directly, not by sorting | Molding-compound makers (GDDR7 and HBM packages), TIM makers, xEV | In production; next-generation GDDR grades in evaluation | Adopted in new GPU projects and multilayer high-speed-memory packages |
| Acetylene black (DENKA BLACK) | High-purity conductive carbon from the acetylene process | High-voltage cable compound makers; ESS and lithium-ion battery cathode makers | Since 1942; new Thailand plant (SCGC JV) under construction | Power-infrastructure demand strong; xEV demand weak in Europe; FY3/27 production constrained by Middle East feedstock |
| ALSINK | High-reliability Al/SiC heat-dissipating base plate for power modules | Power-module makers (rail traction, HVDC, renewables) | Capacity reinforcement announced May 2025 | Strong in power infrastructure and DC transmission |
| Silicon nitride powder | Si₃N₄ powder for heat-dissipation substrates and bearing balls | Ceramic-substrate and bearing makers | In production | Steady replacement demand despite weak EV market |
| Ceramic substrates (Si₃N₄, AlN) | Insulating heat-dissipation substrates | xEV and rail power-module makers | In production | Price increases implemented; xEV weak in Europe |
| High-performance film | Functional films for electronic-component processing | Electronic-component makers | In production | Gradual recovery |
| Electronic packaging / carrier tapes | Conductive and transparent carrier tapes for component transport | Component makers and EMS | Production in China and Vietnam | Part of a long-standing electronics-packaging franchise |
| Electronic circuit substrates ("HITT Plate") | Metal-based insulated substrates | LED and power-electronics makers | Since 1985 (Shibukawa) | — |
| Semiconductor process gases | Monosilane (Denar Silane), arsine (Dalian) | Semiconductor fabs | In production | — |
| Adhesives ("Hard Lock") and industrial tapes (Vinyl Tape) | Structural acrylic adhesives; PVC electrical tape | Industrial, electrical | Hard Lock since 1975 | Vinyl tape made in Vietnam |
| Electrical installation materials | Wiring and installation products | Electrical contractors | — | — |
Life Innovation
| Product line | Description | Target customer | Status |
|---|---|---|---|
| Influenza HA vaccine | Seasonal influenza vaccine produced in eggs (egg-price inflation is a cost factor) | Japanese national immunisation and medical institutions | Shipped as planned each season (manufactured for September shipment) |
| Rapid antigen test kits (QuickNavi™ series) | Point-of-care lateral-flow tests for COVID-19, influenza and others; "combo kits" detect COVID-19 and influenza together | Clinics, hospitals, pharmacies | New reagent manufacturing building at Gosen (Kagamida) operational May 2025; FY3/26 combo-kit shipments rose while COVID-only kits fell |
| IVD clinical reagents | Inflammation markers and other clinical-chemistry and immunology reagents | Hospital and commercial laboratories, overseas distributors | Weak in some overseas markets in FY3/26; expanded by Kainos |
| Kainos Laboratories reagents | Clinical-diagnostic reagents developer and manufacturer (formerly DOMS-IATRON, founded 1975) | Laboratories | Consolidated from March 2026 |
| Oncolytic virus preparation | Virus-based oncology therapeutic (Denka lists it among segment products) | Oncology | — |
| Genetic point-of-care diagnostics (R&D) | Simple gene-based testing systems | Future POCT | R&D at Denka Life Innovation Research (Singapore) |
| Cell culture ware (development) | Culture vessels promoting osteogenic and adipogenic differentiation of mesenchymal stromal/stem cells | Regenerative-medicine and life-science researchers | Showcased at BioJapan, 7–9 Oct 2026 |
| Digital-health investments | Wearable electronic stethoscope (Aevice Health, Jan 2025); wireless wearable ultrasound for blood-flow assessment (Flosonics Medical, Jul 2026) | — | Corporate venture capital (CVC) minority stakes |
| ESD simulator model | Endoscopic submucosal dissection training model | Medical training | Industry-academia project result (Jan 2026) |
Elastomers & Infrastructure Solutions
| Product line | Description | Target customer | Status |
|---|---|---|---|
| Chloroprene rubber (Denka Chloroprene; DPE's neoprene) | Polychloroprene dry rubber and latex | Automotive belts and hoses, adhesives, wetsuits, gloves and medical | Omi only since DPE suspension (May 2025); price revision announced Apr 2026 |
| DENKA ER | Ethylene–vinyl acetate–acrylic ester specialty rubber (heat and oil resistant) | Automotive hoses | Launched 1982; exit announced Jul 2026; production ends Aug 2028, sales end Mar 2030 |
| Special cement additives (Denka CSA and others) | Expansive and rapid-hardening additives, calcium aluminates | Concrete, infrastructure, construction | Imerys technical and business alliance (Sep 2025); plants in Tianjin and Malaysia |
| Fertilisers | Fused phosphate and silicate phosphate fertilisers (Hinode Chemical); humic-acid fertilisers (Denka Azumin) | Agriculture | Ongoing |
| Calcium carbide | Feedstock and industrial chemical | Industrial | Omi |
| Refractories | Heat-resistant materials | Steel and industrial furnaces | Ongoing |
| Polyethylene corrugated pipes | Agricultural and civil-engineering drainage | Construction and agriculture | Sales rose in FY3/26 |
| Carbon-negative concrete "CUCO" | Consortium project for CO₂-absorbing concrete | Construction | R&D and consortium stage |
| Cement | — | — | Production ended June 2025 |
Polymer Solutions
| Product line | Description | Target customer | Status |
|---|---|---|---|
| Styrene monomer | Base monomer (Chiba) | Internal and external | Periodic maintenance in FY3/27; spin-off scope |
| Polystyrene | Via Toyo Styrene (65%) | Packaging, appliances | Consolidated from 31 Mar 2026 |
| ABS / AS resins | Engineering styrenics | Appliances, OA, automotive | Volume up in FY3/26; Middle East cuts in FY3/27 |
| CLEAREN (SBC) | Styrene-butadiene block copolymer, transparent | Packaging, sheets | Singapore and Japan |
| MS resin / transparent resins | Light-guide plates for PC monitors | Display makers | Losing share to Chinese products |
| N-phenylmaleimide heat-resistant resin (Denka IP) | Heat-resistance modifier for ABS | Automotive and appliance compounders | Singapore |
| POVAL | Polyvinyl alcohol | Adhesives, paper, textiles | Ongoing |
| Toyokalon | Synthetic fibre for wigs and hairpieces | Hair-product makers (Africa and the US) | Production consolidated, delivering cost savings |
| Food-packaging sheets and containers | Styrenic sheets and formed containers (Denka Polymer) | Food retailers and processors | Price revisions in FY3/26 |
| Housing materials | Metal gutters and similar (Denka Astec) | Housing | Ongoing |
| D-NODE™ | Brand for a closed-loop styrene resource-circulation (chemical recycling) system | Brand owners | Launched Apr 2025; market rollout of recycled-content products accelerated Aug 2026 |
Financial Narrative
Income statement
Sources and notes: - Annual Securities Reports; FY3/25 and FY3/26 Tanshin; FY3/26 Results Presentation (operating income and depreciation series).
-
Gross profit for FY3/22–FY3/24 comes from S&P Capital IQ data via Yahoo Finance and MarketScreener. FY3/25–FY3/26 come from the Tanshin.
-
Pre-tax income was retrieved only for the latest two years (−¥17.1bn in FY3/25; +¥21.4bn in FY3/26; Tanshin).
-
Ordinary profit is the Japanese-GAAP line after non-operating items. It is shown in place of pre-tax income for the full series.
Diluted EPS equals basic because there are no dilutive shares (Annual Securities Report).
Revenue CAGR:
-
FY3/21 (¥354.4bn) to FY3/26 (¥384.2bn): +1.6% a year.
-
FY3/22 to FY3/26: ≈0.0% a year.
-
Group revenue has been essentially flat for a decade: ¥384.0bn in FY3/15 vs ¥384.2bn in FY3/26. Commodity price pass-through masks mix upgrading.
Commentary.
FY3/22 peak: Operating income reached ¥40.1bn (10.4% margin) on COVID-test demand (Life Innovation ¥15.5bn) and strong semiconductor fillers.
FY3/23–FY3/24 collapse: - Semiconductor inventory correction cut E&I operating income in half to ¥9.0bn by FY3/24.
-
Losses at the DPE chloroprene plant rose: emissions-control constraints, staffing and weather outages.
-
COVID-kit demand normalised.
-
High-cost inventory and higher fixed costs from Mission 2030 investment added pressure.
-
Gross margin fell 6.7pp between FY3/22 and FY3/24.
FY3/25 trough: Operating income was only ¥14.4bn. The DPE impairment (¥16.1bn) and ¥7.9bn liquidation losses produced a ¥12.3bn net loss and negative ROE.
FY3/26 inflection: Operating income rose 82% to ¥26.2bn on sales that fell 4%. Gross margin recovered to 24.5% from three sources:
-
E&I volume of +¥6.7bn from AI and power demand;
-
removal of DPE losses, +¥8.8bn;
-
cost cuts under the Best Practices Project (¥3.7bn of P&L-factored savings).
Net income of ¥15.7bn depended heavily on one-off gains:
-
sale of cross-shareholdings, ¥12.6bn;
-
sale of the Ofuna land, ¥8.2bn;
-
bargain-purchase gain on Toyo Styrene, ¥6.5bn.
These were offset by DPE liquidation losses (¥21.1bn) and a step-acquisition loss (¥4.9bn). Underlying recurring net income is therefore materially lower than reported.
Balance sheet
Sources and notes: - Annual Securities Report; FY3/26 Results Presentation (interest-bearing debt).
- Owners' equity for FY3/22–FY3/24 is derived as equity ratio × total assets. FY3/25–FY3/26 are reported directly (¥296.2bn and ¥310.7bn).
Debt split (¥bn):
Source: FY3/26 Tanshin balance sheet.
Other balance-sheet items (FY3/26):
-
Goodwill ¥2.2bn (Kainos) and other intangibles ¥2.8bn, total ¥5.1bn (FY3/25: ¥3.1bn).
-
Construction in progress ¥79.0bn, up from ¥54.9bn: SNECTON, Thailand acetylene black, ALSINK.
-
Investment securities ¥47.5bn.
-
Working capital (current assets − current liabilities): ¥75.0bn, up from ¥40.0bn. The increase reflects refinancing of short-term debt into long-term borrowings, which raised the current ratio from 1.17x to 1.41x.
-
Non-controlling interests rose to ¥28.1bn from ¥12.1bn (Toyo Styrene 35% and Kainos minorities). DBJ preferred capital at Flowers also contributed to "proceeds from share issuance to non-controlling shareholders" of ¥14.2bn.
Cash flow
Sources and notes: - Annual Securities Report (cash-flow lines); FY3/26 Results Presentation (investment and lending, dividends).
-
Buybacks were zero apart from immaterial odd-lot purchases.
-
FY3/26 purchases of PP&E (cash basis) were ¥67.2bn (FY3/25: ¥58.8bn).
-
FY3/26 investing cash flow was helped by asset-sale proceeds of ¥11.3bn (PP&E) and ¥13.6bn (securities).
Denka has generated cumulative negative free cash flow of about −¥107bn over five years, financed by debt; interest-bearing debt rose by ¥85bn. FY3/23 operating cash flow collapsed to ¥8.9bn on inventory build. Management guides capex down to ¥47.0bn in FY3/27 after the FY3/25 peak (¥70.0bn), which should move free cash flow back toward break-even.
Ratios
Sources and notes: - ROE, ROIC, net D/E, DOE and total return come from the FY3/26 Results Presentation.
-
Interest coverage and Debt/OCF come from the FY3/26 Tanshin (company-defined, cash-flow based).
-
The other ratios are analyst calculations.
-
Total return for FY3/25 is not meaningful because of the net loss; it is shown as 0 for charting.
-
Accounting interest coverage (operating income / interest expense) was 12.5x in FY3/26 (¥26.2bn / ¥2.10bn) and 6.9x in FY3/25.
Cash conversion cycle (analyst calculation, year-end balances):
The roughly 160-day inventory cycle is structurally long. It reflects:
-
vaccine and diagnostic stock build for the influenza season;
-
chloroprene inventories;
-
raw-material safety stocks.
FY3/26 inventories fell ¥14.1bn in cash-flow terms, but days lengthened because cost of sales fell faster.
Trend synthesis. Every return metric bottomed in FY3/24–FY3/25 and recovered in FY3/26, but remains well below the FY3/22 level and below Denka's estimated cost of equity. Leverage has risen materially: net debt/EBITDA went from 1.8x to 3.4x. The equity ratio of 45.6% and the JCR A+ / R&I A ratings still give headroom. Financial strategy in Phase 2 depends on capex normalising and DPE cash costs ending.
Quarterly trajectory
Source: Q1 FY3/27 Results Presentation (7 Aug 2026).
Q1 FY3/27 included about ¥6.0bn of inventory gains (Polymer Solutions +¥4.8bn), which the company says may reverse. Excluding these gains, underlying Q1 operating income was about ¥5.0bn.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents and main products | Key operating entities |
|---|---|---|
Electronics & Innovative Products | Fused silica and spherical silica, spherical alumina, electronic circuit substrates, fine ceramics (silicon nitride, aluminium nitride), electronic packaging (carrier tapes), acetylene black, electrical installation materials, adhesives, adhesive tape, semiconductor process materials (monosilane, arsine), SNECTON | Parent (Omuta, Shibukawa, Isesaki, Omi); Denar Silane; Denka Advantec and Denka Singapore (SG); Denka Fine Materials Suzhou; Denka Electronic Materials Dalian; Denka Advanced Materials Vietnam; Denka SCGC (TH) |
Life Innovation | Influenza vaccines, rapid-antigen diagnostic kits (QuickNavi), clinical IVD reagents, oncolytic virus preparation | Parent (Gosen/Kagamida sites); Kainos Laboratories (from Mar 2026); Denka Life Innovation Research (SG); Icon Genetics (DE) |
Elastomers & Infrastructure Solutions | Chloroprene rubber, DENKA ER (exit announced), fertilisers, calcium carbide, refractories, special cement additives, polyethylene corrugated pipes | Parent (Omi, Chiba); DPE (US, suspended); Hinode Chemical; Denka Azumin; Denka Inorganic Materials Tianjin; Denka Infrastructure Malaysia |
Polymer Solutions | Styrene monomer, ABS, AS, SBC (CLEAREN), N-phenylmaleimide heat-resistant resin, transparent and MS resins, POVAL, Toyokalon wig fibre, food-packaging sheets and containers | Parent (Chiba); Toyo Styrene (65% from 31 Mar 2026); Denka Polymer; Denka Astec; Denka Singapore; Denka Advantec; Denac (affiliate) |
Others | Plant engineering, trading/wholesale (Akros Trading / YK Acros), power supply (Kurobegawa Electric Power, affiliate) | Denka Engineering; Akros Trading |
Segment net sales (JPY Bn)
| Segment net sales (JPY Bn) | FY3/24 | FY3/25 | FY3/26 | FY3/27F |
|---|---|---|---|---|
Electronics & Innovative Products | 87.8 | 92.2 | 104.4 | 110.0 |
Life Innovation | 47.1 | 43.3 | 40.5 | 45.0 |
Elastomers & Infrastructure Solutions | 111.4 | 111.7 | 97.6 | 105.0 |
Polymer Solutions | 124.2 | 135.4 | 124.2 | 170.0 |
Others | 18.8 | 17.7 | 17.6 | 20.0 |
Total | 389.3 | 400.3 | 384.2 | 450.0 |
Segment operating income (JPY Bn)
| Segment operating income (JPY Bn) | FY3/20 | FY3/21 | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 | FY3/27F |
|---|---|---|---|---|---|---|---|---|
Electronics & Innovative Products | 12.7 | 14.2 | 18.7 | 18.0 | 9.0 | 9.2 | 13.9 | 13.0 |
Life Innovation | 7.0 | 14.8 | 15.5 | 14.4 | 11.7 | 9.6 | 6.2 | 6.0 |
Elastomers & Infrastructure Solutions | 3.9 | -3.6 | -3.5 | -1.1 | -9.3 | -8.0 | 0.1 | 7.0 |
Polymer Solutions | 7.1 | 8.4 | 7.9 | -1.2 | -0.1 | 1.2 | 3.6 | 2.0 |
Consolidated operating income | 31.6 | 34.7 | 40.1 | 32.3 | 13.4 | 14.4 | 26.2 | 30.0 |
Segment Overview — E&I
| Segment | Sales JPY Bn | YoY sales % | OI JPY Bn | YoY OI JPY Bn | OI margin % | % of group sales | Segment assets JPY Bn | Depreciation JPY Bn |
|---|---|---|---|---|---|---|---|---|
E&I | 104.4 | +13.3 | 13.9 | +4.7 | 13.3 | 27.2 | 255.6 | 11.2 |
Life Innovation | 40.5 | -6.3 | 6.2 | -3.4 | 15.4 | 10.5 | 72.3 | 4.2 |
E&IS | 97.6 | -12.6 | 0.07 | +8.0 | 0.1 | 25.4 | 145.5 | 8.3 |
Polymer Solutions | 124.2 | -8.3 | 3.6 | +2.4 | 2.9 | 32.3 | 119.6 | 5.2 |
Others | 17.6 | -1.1 | 2.4 | 0.0 | 13.8 | 4.6 | 48.8 | 0.4 |
Group | 384.2 | -4.0 | 26.2 | +11.8 | 6.8 | 100.0 | 681.0 | 29.2 |
Segment ROIC (%)
| Segment ROIC (%) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 | FY3/27F |
|---|---|---|---|---|---|---|
Electronics & Innovative Products | 14.7 | 12.1 | 5.4 | 4.5 | 5.7 | 4.8 |
Life Innovation | 17.8 | 15.3 | 13.8 | 10.8 | 6.6 | 6.0 |
Elastomers & Infrastructure Solutions | -2.5 | -0.3 | -5.4 | -4.9 | 0.3 | 5.5 |
Polymer Solutions | 9.6 | -1.3 | 0.0 | 1.6 | 3.3 | 2.3 |
Consolidated | 7.3 | 6.7 | 2.5 | 2.5 | 4.2 | 4.5 |
Financial Analysis
| Metric (JPY Bn) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|---|---|
Net sales | 384.8 | 407.6 | 389.3 | 400.3 | 384.2 |
Gross profit | 107.2 | 102.3 | 82.5 | 84.6 | 94.3 |
Operating income | 40.1 | 32.3 | 13.4 | 14.4 | 26.2 |
Depreciation | 23.9 | 27.0 | 26.9 | 27.9 | 29.2 |
EBITDA (OI + depreciation) | 64.0 | 59.3 | 40.3 | 42.3 | 55.4 |
Ordinary profit | 36.5 | 28.0 | 5.5 | 7.6 | 19.3 |
Net income attributable to owners | 26.0 | 12.8 | 11.9 | -12.3 | 15.7 |
Comprehensive income | 31.7 | 20.9 | 19.3 | -7.1 | 19.1 |
Total assets | 557.6 | 592.2 | 616.2 | 655.5 | 681.0 |
Cash and equivalents | 20.2 | 20.2 | 35.4 | 37.0 | 35.3 |
Interest-bearing debt total | 137.0 | 169.7 | 174.4 | 217.7 | 221.7 |
Net debt | 116.8 | 149.5 | 139.0 | 180.7 | 186.4 |
Shareholders' equity (owners) | 288.3 | 296.7 | 307.5 | 296.2 | 310.7 |
Total net assets (incl. NCI) | 292.1 | 300.4 | 316.9 | 308.3 | 338.8 |
Equity ratio (%) | 51.7 | 50.1 | 49.9 | 45.2 | 45.6 |
Operating cash flow | 42.6 | 8.9 | 36.3 | 18.6 | 36.2 |
Investing cash flow | -36.8 | -28.3 | -22.6 | -59.6 | -45.0 |
Capex (investment and lending, company basis) | 35.6 | 39.4 | 44.0 | 70.0 | 60.8 |
Free cash flow (OCF − capex) | 7.0 | -30.5 | -7.7 | -51.4 | -24.6 |
Financing cash flow | -12.3 | 18.4 | 0.7 | 40.1 | 7.6 |
Dividends declared (total) | 12.5 | 8.6 | 8.6 | 8.6 | 8.6 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Per share (JPY)
| Per share (JPY) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|---|---|
EPS basic | 301.67 | 148.08 | 138.61 | -142.73 | 182.10 |
EPS diluted | 301.67 | 148.08 | 138.61 | -142.73 | 182.10 |
Dividend per share | 145 | 100 | 100 | 100 | 100 |
Book value per share | 3,345.34 | 3,438.28 | 3,568.69 | 3,436.95 | 3,604.53 |
Margins (%)
| Margins (%) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|---|---|
Gross margin | 27.9 | 25.1 | 21.2 | 21.1 | 24.5 |
Operating margin | 10.4 | 7.9 | 3.4 | 3.6 | 6.8 |
EBITDA margin | 16.6 | 14.5 | 10.4 | 10.6 | 14.4 |
Net margin | 6.8 | 3.1 | 3.1 | -3.1 | 4.1 |
Debt composition (JPY Bn)
| Debt composition (JPY Bn) | FY3/25 | FY3/26 |
|---|---|---|
Short-term borrowings | 74.7 | 51.8 |
Commercial paper | 33.0 | 20.0 |
Current portion of bonds | 15.0 | 15.0 |
Current portion of long-term borrowings | 0.0 | 0.2 |
Short-term debt subtotal | 122.7 | 87.0 |
Bonds (non-current) | 15.0 | 10.0 |
Long-term borrowings | 80.0 | 124.8 |
Long-term debt subtotal | 95.0 | 134.8 |
Financial Analysis — ROE
| Ratio | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|---|---|
ROE (%) | 9.4 | 4.4 | 4.0 | -4.1 | 5.2 |
ROA, net income / year-end total assets (%) | 4.7 | 2.2 | 1.9 | -1.9 | 2.3 |
ROIC, company basis (%) | 7.3 | 6.7 | 2.5 | 2.5 | 4.2 |
Gross debt / equity (x) | 0.48 | 0.57 | 0.57 | 0.73 | 0.71 |
Net D/E, company basis (x) | 0.40 | 0.50 | 0.45 | 0.61 | 0.60 |
Net debt / EBITDA (x) | 1.8 | 2.5 | 3.4 | 4.3 | 3.4 |
Interest coverage, OCF / interest paid (x) | 45.4 | 8.1 | 21.7 | 8.9 | 17.7 |
Debt / OCF (years) | 3.2 | 19.0 | 4.8 | 11.7 | 6.1 |
Asset turnover, sales / year-end assets (x) | 0.69 | 0.69 | 0.63 | 0.61 | 0.56 |
Dividend on equity, DOE (%) | 4.5 | 2.9 | 2.9 | 2.9 | 2.8 |
Total return ratio (%) | 48 | 68 | 72 | 0 | 55 |
Financial Analysis — DSO
| Metric (days) | FY3/25 | FY3/26 |
|---|---|---|
DSO (receivables / sales × 365) | 80 | 84 |
DIO (inventory / COGS × 365) | 151 | 160 |
DPO (payables / COGS × 365) | 56 | 54 |
Cash conversion cycle | 176 | 190 |
Revenue History
| Quarter | Net sales | Operating income | OI margin % |
|---|---|---|---|
Q1 FY3/25 | 95.2 | 4.7 | 4.9 |
Q2 FY3/25 | 103.8 | 4.7 | 4.5 |
Q3 FY3/25 | 102.5 | 2.4 | 2.3 |
Q4 FY3/25 | 98.7 | 2.6 | 2.6 |
Q1 FY3/26 | 94.1 | 2.3 | 2.4 |
Q2 FY3/26 | 102.6 | 7.4 | 7.2 |
Q3 FY3/26 | 94.1 | 8.5 | 9.0 |
Q4 FY3/26 | 93.5 | 8.0 | 8.6 |
Q1 FY3/27 | 97.0 | 11.0 | 11.3 |
Q2 FY3/27F | 108.0 | 6.0 | 5.6 |
Region net sales (JPY Bn)
| Region net sales (JPY Bn) | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|
Japan | 226.2 | 221.7 | 214.3 |
Asia (ex-Japan) | 98.0 | 114.4 | 106.0 |
Other regions (Americas, Europe, other) | 65.1 | 64.2 | 63.9 |
Total | 389.3 | 400.3 | 384.2 |
Region share and growth (%) | FY3/24 | FY3/25 | FY3/26 |
Japan share | 58.1 | 55.4 | 55.8 |
Asia share | 25.2 | 28.6 | 27.6 |
Other share | 16.7 | 16.0 | 16.6 |
Overseas share total | 41.9 | 44.6 | 44.2 |
Japan YoY growth | — | -2.0 | -3.3 |
Asia YoY growth | — | 16.8 | -7.3 |
Other YoY growth | — | -1.4 | -0.4 |
Annual Price Range Details
| Annual price range (JPY) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
|---|---|---|---|---|---|
High | 4,535 | 3,620 | 2,909 | 2,384 | 3,750 |
Low | 3,190 | 2,510 | 2,343 | 1,717 | 1,744 |
5-year TSR index (Mar 2021 = 100) | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 |
Denka TSR | 80.2 | 67.4 | 60.9 | 58.4 | 92.2 |
Nikkei 225 Total Return | 97.2 | 100.2 | 147.0 | 132.2 | 192.9 |
Valuation Multiples
| Multiple | Denka |
|---|---|
P/E, trailing (FY3/26 EPS ¥182.10) | ≈17.6x (Yahoo: 17.7x) |
P/E, forward (FY3/27 guided EPS ¥185.67) | ≈17.2x |
P/B (BPS ¥3,604.53) | ≈0.89x |
EV (market cap + net debt ¥186.4bn + NCI ¥28.1bn) | ≈¥495bn |
EV/EBITDA (FY3/26 EBITDA ¥55.4bn) | ≈8.9x |
EV/Sales (FY3/26) | ≈1.29x |
Dividend yield (¥100) | ≈3.1% |
Capital Markets
| Item | Value | Source |
|---|---|---|
Average target price | ¥4,502.5 (high ¥5,300; low ¥3,160) | Yahoo Finance, Sep–Oct 2026 |
TradingView range | Max ¥5,300; min ¥4,000 | Jul 2026 |
Consensus next-year EPS | ¥171 | Stockopedia, Apr 2026 |
Q1 FY3/27 operating income consensus | ¥5.6bn (actual ¥11.0bn) | Bloomberg via Investing.com |
Dividend metric
| Dividend metric | FY3/22 | FY3/23 | FY3/24 | FY3/25 | FY3/26 | FY3/27F |
|---|---|---|---|---|---|---|
DPS (JPY) | 145 | 100 | 100 | 100 | 100 | 100 |
Total dividends (JPY Bn) | 12.5 | 8.6 | 8.6 | 8.6 | 8.6 | 8.6 |
Payout ratio consolidated (%) | 48 | 68 | 72 | 0 | 55 | 54 |
Credit Ratings
| Agency | Long-term | Outlook | Short-term | Latest action |
|---|---|---|---|---|
JCR | A+ | Stable | J-1 | New bond rated A+ (3 Jul 2026); shelf A+ (10 Apr 2026) |
R&I | A | Stable | a-1 | Affirmed 22 Sep 2025; shelf preliminary A (10 Apr 2026) |
Moody's / S&P / Fitch | Not rated | — | — | — |
Analyst Conclusions
Management guidance (FY3/27, as of 7 Aug 2026)
| Item | 1H FY3/27 revised | Full year FY3/27 (unchanged) |
|---|---|---|
| Net sales | ¥205.0bn | ¥450.0bn |
| Operating income | ¥17.0bn (from ¥12.0bn) | ¥30.0bn |
| Ordinary profit | ¥11.0bn | ¥20.0bn |
| Net income | ¥0.0bn | ¥16.0bn (EPS ¥185.67) |
| Assumptions | ¥160.4/USD; naphtha ¥99,300/kl | ¥158/USD; naphtha ¥123,250/kl |
Management expects to review full-year guidance with 1H results on 9 November 2026. The main risks it flags are reversal of inventory gains and Middle East and feedstock uncertainty.
Implied 2H operating income is only ¥13.0bn (¥30.0bn − ¥17.0bn), versus 2H FY3/26's ¥16.5bn. This looks conservative if feedstock normalises.
Bull case
-
AI materials re-rate E&I. SNECTON's full-swing AI sales from 2H FY3/27, continued low-Df silica and GDDR/HBM alumina growth, and the new organic filler could take E&I operating income back toward its FY3/22 peak of ¥18.7bn by FY3/29. Segment ROIC could recover from 5.7% to above 10%. Q1 FY3/27 E&I operating income was already ¥3.7bn (+48% YoY).
-
Self-help is largely in hand. DPE removal adds +¥15.0bn versus FY3/25 by FY3/27. Best Practices savings rise to ¥6.8bn. E&IS swings from −¥8.0bn (FY3/25) to +¥7.0bn guidance (FY3/27). This visible, non-market-dependent profit bridge supports the Phase 2 path to ¥45bn operating income and ROE of at least 8%.
-
Portfolio simplification unlocks value. A styrene spin-off by April 2027 would move about a third of sales (PS ¥124bn, 2.9% margin) out of the core. Higher group margins and lower capex intensity could close the P/B discount (0.89x). Capex falling from ¥70bn to ¥47bn should turn free cash flow positive.
Bear case
-
Earnings quality is weak. FY3/26 net income relied on about ¥27bn of one-off gains. Q1 FY3/27 operating income included ¥6.0bn of inventory gains that management warns may reverse. DPE extraordinary losses continue (¥4.8bn in Q1). Net income of ¥16bn in FY3/27 implies ROE of only about 5%, far from 8%.
-
Balance-sheet stretch and negative free cash flow. Five-year cumulative free cash flow is about −¥107bn. Net debt/EBITDA is 3.4x. Dividends of ¥8.6bn a year are not covered by free cash flow. Any AI-cycle pause or prolonged Middle East disruption could force a choice between the dividend and capex.
-
Legacy and cyclical drag persists. Chloroprene is in structural decline (230 kt global demand). Life Innovation operating income fell to ¥6.2bn and 1H guidance was cut again. Styrenics face Chinese competition. The five-year TSR of −7.8% against +92.9% for the Nikkei TR shows repeated failure to deliver on plans (the original Mission 2030 targets were abandoned).
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 9 Nov 2026 | 1H FY3/27 results; full-year guidance review; size of inventory-effect reversal |
| 2H FY3/27 | SNECTON AI-volume ramp; hard-type SNECTON capacity decision; low-Df filler adoption |
| Ongoing | Middle East feedstock normalisation (assumed from October 2026); naphtha price path |
| By early FY3/28 | DPE closure plan; final exit costs; Mitsui cost sharing; any residual US litigation |
| By Apr 2027 | Styrene spin-off structure (scope, partners, Toyo Styrene role) |
| Winter 2026/27 | Influenza and COVID season, which drives antigen-kit demand |
| Ongoing | Kainos integration; possible minority squeeze-out |
| May 2027 | FY3/27 results; FY3/28 guidance against the Phase 2 plan (operating income ¥40bn) |
| Jun 2027 | AGM votes on directors (ISS/ROE screen); board-independence refresh |
| Ongoing | Thailand acetylene black plant start-up; ALSINK capacity |
Analyst verdict
Denka is a company in transition whose investment case now rests on whether a genuinely differentiated AI- and power-materials franchise can outgrow a large and still-volatile legacy base. FY3/26 marked a real operational inflection: operating income almost doubled to ¥26.2bn on sales that fell 4%. Three things drove it: AI-related E&I volume, the decisive suspension of the loss-making US chloroprene plant, and measurable cost cuts. Q1 FY3/27 extended that trend to an 11.3% operating margin, the highest in years.
Several factors argue against extrapolating that run-rate:
-
Reported profits still carry heavy one-off items in both directions.
-
The Q1 beat was roughly half inventory gains that management expects may reverse.
-
Free cash flow has been negative for four of the last five years, and leverage has risen to 3.4x net debt/EBITDA.
-
Management's credibility is partly rebuilt but not restored. The original Mission 2030 targets of ¥100bn operating income and ROE of 15% have effectively been replaced by more modest Phase 2 goals, and proxy advisers have challenged the leadership's returns record.
The equity at about ¥3,200 trades below book (0.89x P/B) and at about 17x guided earnings. On normalised earnings this is not demanding if Phase 2's ¥40–45bn operating income is achieved, but it is not distressed either. The consensus target of about ¥4,500 implies the market is giving partial credit. Upside in the share price depends on three things that are within management's control and verifiable within 12 months:
-
clean execution of the DPE closure without new liabilities;
-
a credible styrene separation by April 2027;
-
visible SNECTON and low-Df revenue scaling in 2H FY3/27.
Verdict: a constructive but execution-dependent "show-me" story. The quality of the AI-materials franchise justifies close monitoring and selective accumulation on drawdowns. Conviction should be sized against the balance-sheet and earnings-quality risks until free cash flow turns sustainably positive and ROE reaches at least 7%.
Source notes
Denka primary documents: - 167th Annual Securities Report (17 Jun 2026)
-
FY3/26 Consolidated Financial Results (13 May 2026)
-
FY3/26 Results Presentation (13 May 2026) and script
-
Q1 FY3/27 Results Presentation (7 Aug 2026)
-
Mission 2030 Phase 2 notice and presentation (27 Feb 2026)
-
Styrene spin-off notice (27 Feb 2026)
-
DENKA ER withdrawal (17 Jul 2026)
-
Extraordinary-loss notice (7 Aug 2026)
-
Imerys alliance release (1 Sep 2025)
-
ISS response (2 Jun 2025)
-
Ofuna asset-sale notice (28 Mar 2025)
-
Toyo Styrene consolidation notice (9 Mar 2026)
-
Kainos tender offer notices (Feb–Mar 2026)
-
Company website: officers (1 Apr 2026); shareholder data (31 Mar 2026); news lists 2025–2026
-
Denka Sustainability Site
Third-party sources: - US EPA (RCRA settlement summary)
-
Fox8, Manufacturing Dive, Rubber News, C&EN, Chemistry World, European Rubber Journal (DPE coverage)
-
DuPont 10-Q (FY2025)
-
JCR and R&I rating pages
-
Yahoo Finance, StockAnalysis, Stockopedia, TradingView (market data)
-
MarketScreener / S&P Capital IQ (gross profit, R&D history)
-
Investing.com (Q1 FY3/27 consensus)
-
Tosoh FY3/26 results; Resonac FY2025 results; The Shashi (Daicel comparison)
-
Kabutan and gBizINFO (shareholders, auditor)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Independent? | Born / age (Oct 2026) | Joined board | Background |
|---|---|---|---|---|---|
Toshio Imai | Chairman & Representative Director | No (former CEO) | 25 Jan 1959 / 67 | Director since Jun 2019 | Joined 1982; styrene and elastomer businesses; Corporate Planning GM; President & CEO Apr 2021 – Mar 2025 |
Ikuo Ishida | Representative Director, President & CEO | No | 7 Mar 1962 / 64 | Director since Jun 2023 | Joined 1985; career in electronics materials (functional films, advanced fillers, specialty materials); E&I division GM from 2019; CEO since Apr 2025 |
Rimiru Hayashida | Director, Senior Managing Executive Officer; CFO & CSCO | No | — | Jun 2025 | Joined 1985; Accounting GM; CFO since Jun 2024 |
Masanobu Kosaka | Director, Managing Executive Officer; CTO | No | — | Jun 2025 | Joined 1985; Omi Plant GM; former Vice President of DPE |
Rumiko Nakata | Outside Director | Yes | — | Jun 2024 | Esso; Pfizer Japan HR corporate officer; Mitsubishi Chemical director (HR, D&I); outside director at Kyowa Kirin |
Mizuhiro Uchida | Director (full-time Audit & Supervisory Committee member) | No | 24 Sep 1961 / 65 | Jun 2023 | Internal audit and internal control at Denka |
Toshio Kinoshita | Outside Director (ASC member) | Yes | 12 Apr 1949 / 77 | Outside auditor 2015; outside director since 2019 | CPA; PwC North America senior managing partner; former JICPA chief executive; former outside roles at Panasonic and Mizuho Bank |
Akio Yamamoto | Outside Director (ASC member) | Yes, but ex-Mitsui & Co., which is DPE's 30% partner and a shareholder | 2 Dec 1951 / 74 | Jun 2015 | Mitsui & Co. executive officer; President of Mitsui Bussan Plastic Trade |
Miyuki Matoba | Outside Director (ASC member) | Yes | 15 Aug 1973 / 53 | Jun 2021 | Lawyer; former Japan Federation of Bar Associations executive governor; legal and compliance at MOS Food Services and Nitto Kohki |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role |
|---|---|
Ikuo Ishida | President & CEO |
Rimiru Hayashida | Senior MEO; CFO, CSCO; Accounting, Finance, Corporate Communications, Purchasing, Logistics |
Masanobu Kosaka | MEO; CTO; Production Engineering, New Business Development, Technology Planning, Sustainability Promotion, Digital Strategy & Innovation |
Kei Hara | MEO; CHRO, CCO; Corporate Planning, Best Practice Promoting, HR, Denka Corporation (US), Denka Chemicals GmbH, China business |
Hiroto Horiuchi | MEO; President, Akros Trading |
Michio Kawamura | MEO; Omi Plant |
Masahiro Kawai | EO; Managing Director, DCHA / DSPL / DAPL (Singapore) |
Takeshi Hagiwara | EO; Omuta Plant |
Masahiro Omata | EO; Polymer Solutions |
Tetsuo Noguchi | EO; Gosen site |
Koji Nishimura | EO; Production Engineering |
Taro Inada | EO; Life Innovation (also Representative Director of Flowers Co., the Kainos acquisition vehicle) |
Akinori Adachi | EO; Administrative, Legal, Secretary, Internal Control |
Hiromichi Awada | EO; Chiba Plant |
Akira Kasahara | EO; GM Accounting |
Koya Takahashi | EO; Elastomers & Infrastructure Solutions |
Masahide Yamada | EO; New Business Development |
Tomoya Kowada | EO; Electronics & Innovative Products |
Jun Nakamoto | EO; President, DPE |
Osamu Kunitomo | EO; Shibukawa Plant |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
7 Feb 2025 (effective Apr 2025) | Ishida succeeds Imai as President & CEO; Imai becomes Chairman | Handover to an electronics-materials leader amid the DPE crisis |
Jun 2025 | Hayashida (CFO) and Kosaka (CTO) join the board | Board refresh |
Jun 2025 AGM | ISS recommends voting AGAINST Imai and Ishida because 5-year average ROE is below 5%; company publicly rebuts | Shareholder-pressure signal |
26 Dec 2025; 6 Feb 2026 | Executive officer reshuffles | Alignment with Phase 2 |
Jun 2026 | 167th AGM | — |
Major Shareholders
| Rank | Holder | Shares (100s) | % |
|---|---|---|---|
| 1 | The Master Trust Bank of Japan (trust account) | 157,575 | 18.27 |
| 2 | Custody Bank of Japan (trust account) | 110,854 | 12.85 |
| 3 | Mizuho Trust & Banking — retirement benefit trust, Mizuho Bank account | 32,158 | 3.73 |
| 4 | State Street Bank and Trust Co. 505001 | 26,740 | 3.10 |
| 5 | Taiju Life Insurance | 23,816 | 2.76 |
| 6 | Nomura Trust & Banking (investment trust account) | 21,780 | 2.52 |
| 7 | Custody Bank of Japan (trust account 4) | 19,624 | 2.27 |
| 8 | State Street Bank and Trust Co. 505223 | 15,859 | 1.84 |
| 9 | Denka Employee Shareholding Association | 15,828 | 1.83 |
| 10 | JP Morgan Securities Japan | 12,673 | 1.47 |
Competitive Landscape
Competitors by Segment
| Segment / product | Key competitors | Denka's relative position |
|---|---|---|
Spherical silica and alumina fillers | Admatechs (Toyota group); Nippon Steel Chemical & Material (Micron); Tatsumori; Chinese suppliers | One of the leading global suppliers of spherical fused silica; strong in fine and high-purity grades; well placed in AI substrates |
Low-dielectric resins (SNECTON) | SABIC (PPE-based low-Df resins); Asahi Kasei (PPE); Mitsubishi Gas Chemical | New entrant with a differentiated processability claim; certified at multiple CCL makers |
Acetylene black and conductive carbon | Orion Engineered Carbons; Cabot; Imerys Graphite & Carbon; Lion Specialty Chemicals (Ketjenblack); Chinese acetylene black makers | High purity from the carbide route; leader in HV-cable grades; pressured by Chinese supply in batteries |
Ceramic substrates and Si₃N₄ | Toshiba Materials; Kyocera; Maruwa; UBE (Si₃N₄ powder); Rogers (curamik) | Integrated from powder to substrate |
AlSiC (ALSINK) | Niche Western and Asian suppliers | Strong in rail and HVDC |
Chloroprene rubber | Tosoh (Skyprene); Arlanxeo (Baypren); Chinese producers | Remains among the top global producers via Omi after DPE; market declining (about 230 kt a year) |
Special cement additives | Sika; Imerys (now also a partner); Taiheiyo Materials; Chinese producers | Japanese leader in CSA expansive additives |
Influenza vaccine (Japan) | BIKEN; KM Biologics; Daiichi Sankyo Biotech | One of a small number of domestic producers |
Rapid antigen and IVD | Fujirebio (H.U. Group); Sekisui Medical; Abbott; Roche; Fujifilm; Tauns | Strong POCT brand in Japan; small globally |
Styrenics (SM, ABS, PS, SBC, MS) | PS Japan (Asahi Kasei / Idemitsu / Mitsui Chemicals); Techno-UMG; Toray (ABS); Chi Mei; LG Chem; INEOS Styrolution; Chinese producers | Sub-scale; losing MS share to China; spin-off review |
Wig fibre (Toyokalon) | Kaneka (Kanekalon); Chinese PVC-fibre makers | Second global brand behind Kaneka (analyst view) |
Diversified Japanese chemical peers (corporate level) | Tosoh; Resonac; Daicel; Shin-Etsu Chemical; Sumitomo Bakelite | Smaller, more diversified, lower margin than specialty leaders |
Peer Comparison
| Company (latest FY) | Revenue JPY Bn | Revenue growth % | Operating margin % | Net income JPY Bn | R&D intensity % |
|---|---|---|---|---|---|
Denka (FY3/26) | 384.2 | -4.0 | 6.8 | 15.7 | 3.9 |
Tosoh (FY3/26) | 1,019.9 | -4.1 | 9.4 | 41.6 | — |
Resonac (FY12/25, IFRS) | 1,347.1 | -3.2 | 8.1 (core); 3.5 (IFRS) | 29.0 | — |
Daicel (FY3/26) | about 580 | — | 7.3 | — | — |
Recent Developments
--



